HealthQuill argenx SE
Amgen Inc.’s experimental drug to treat patients suffering from a rare muscle-weakening disease, myasthenia gravis, has shown positive results in an end-stage trial and the California-based company has started talks with regulators for its approval.
Drugs Health Pharma

Amgen’s trial drug to fight autoimmune disorder improves patient outcomes

Amgen Inc.’s experimental drug to treat patients suffering from a rare muscle-weakening disease, myasthenia gravis, has shown positive results in an end-stage trial.

Read More
Eli Lilly’s Alzheimer’s experimental drug, donanedab, slowed down cognitive and functional decline in people with early symptoms of the disease, according to a company statement.
Drugs Medical Pharma

Argenx’s Vyvgart faces setback in autoimmune treatment trial

HQ Team November 28, 2023: Argenx SE, a Belgian biopharmaceutical announced that its experimental drug Vyvgart Hytrulo failed in trials in treating immune.

Read More